GI Dynamics, the creator of the EndoBarrier device designed to target the underlying cause of type 2 diabetes, has announced it has changed its name to Morphic Medical and has rebranded the device formerly known as the EndoBarrier, to RESET. According to the company, the change the reflects the evolving landscape of the industry and Morphic Medical's commitment to driving innovation in patient care.
"We are thrilled to unveil Morphic Medical and RESET as we embark on this exciting chapter in our company's history," said Joseph Virgilio, President & CEO of Morphic Medical. "This re-emergence signifies our dedication to delivering innovative solutions designed to target the underlying causes of type 2 diabetes. With Morphic Medical's approach, and the RESET product, which has been refined through continuous generation of research and clinical data, we are confident in the significant positive impact we will have on patients' lives."
The rebranding of both the company and its products carries two powerful connotations. First, Morphic Medical's devices empower patients to "morph" into a healthier state, effectively combating diabetes and obesity to improve metabolic health and management of their disease. Additionally, the company has undergone a significant evolution, aligning its strategy and approach with the current understanding of the disease.
Morphic Medical's commitment to advancing healthcare has driven this transformation, leading to a better-equipped organisation prepared to address the challenges posed by type 2 diabetes today. The RESET product is designed to help patients' metabolic system reestablish itself and its ability to benefit from diet and exercise therapies, and as indicated by its name, offers patients a fresh start in navigating their journey with type 2 diabetes.
The rebranding coincides with new clinical studies being conducted in the US and India designed to substantiate RESET's safety and efficacy in treating type 2 diabetes and obesity. These studies will supplement the 65+ publications and over 3000 implanted RESET devices demonstrating an ability to reduce A1c and weight in a meaningful manner.
RESET is not approved for sale in the US and is limited by federal law to investigational use only.